Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Q BioMed, Mannin Research Advance AKI Treatment | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Q BioMed, Mannin Research Advance AKI Treatment

Data shows that the Ang-Tie2 signaling pathway is a promising therapeutic target to prevent AKI

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Q BioMed Inc., a commercial stage biotech company, and its technology research partner Mannin Research Inc., presented positive data on a potential new treatment for acute kidney injury (AKI).   
There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the U.S.  Current treatments for AKI are mainly supportive and do not treat the underlying condition.

Mannin’s chief scientific officer, Dr. Susan Quaggin, presented data that showed that the Ang-Tie2 signaling pathway is a promising therapeutic target to prevent AKI after ischemia caused by ischemia–reperfusion (IR) injury to the kidney.  Ischemia in the kidney occurs in a range of clinically important scenarios such as hypotension, sepsis, and cardiovascular events such as strokes.

“We are very encouraged by this data. Taken together with our recently announced funding and establishment of a research center in Saxony, Germany, this data will enable us to advance our program in developing therapeutics to treat acute kidney injury, bolstering our pipeline,” said Dr. Nikopoulos. “We look forward to the day when we can make a difference in the lives of patients with kidney and cardiovascular diseases.”

Q BioMed and Mannin have been partners since 2015 and Q BioMed has an exclusive option on all Mannin portfolio assets.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics